SWOG Cancer Research Network - Leslie Ballas on Bladder Preservation in MIBC: S2427 BRIGHT Trial Update
@swog.org
oncodaily.com/blog/leslie-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SWOG #BladderCancer #MIBC #S2427BRIGHT
@swog.org
oncodaily.com/blog/leslie-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SWOG #BladderCancer #MIBC #S2427BRIGHT
Leslie Ballas on Bladder Preservation in MIBC: S2427 BRIGHT Trial Update - SWOG Cancer Research Network - OncoDaily
Leslie Ballas on Bladder Preservation in MIBC: S2427 BRIGHT Trial Update - SWOG Cancer Research Network / bladder cancer, cancer, Leslie Ballas, MIBC,
oncodaily.com
May 5, 2025 at 4:56 PM
SWOG Cancer Research Network - Leslie Ballas on Bladder Preservation in MIBC: S2427 BRIGHT Trial Update
@swog.org
oncodaily.com/blog/leslie-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SWOG #BladderCancer #MIBC #S2427BRIGHT
@swog.org
oncodaily.com/blog/leslie-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SWOG #BladderCancer #MIBC #S2427BRIGHT
Defining New Endpoints and Designing Next-Generation Trials in MIBC - Ashish M. Kamat
oncodaily.com/blog/next-ge...
@ashishkamatmd.bsky.social
#Cancer #OncoDaily #Oncology #Medicine #Health
oncodaily.com/blog/next-ge...
@ashishkamatmd.bsky.social
#Cancer #OncoDaily #Oncology #Medicine #Health
Ashish M. Kamat: Defining New Endpoints and Designing Next-Generation Trials in MIBC - OncoDaily
Ashish M. Kamat: Defining New Endpoints and Designing Next-Generation Trials in MIBC / Andrea Necchi, Ashish M. Kamat, cancer, OncoDaily, Oncology
oncodaily.com
December 12, 2024 at 3:44 PM
Defining New Endpoints and Designing Next-Generation Trials in MIBC - Ashish M. Kamat
oncodaily.com/blog/next-ge...
@ashishkamatmd.bsky.social
#Cancer #OncoDaily #Oncology #Medicine #Health
oncodaily.com/blog/next-ge...
@ashishkamatmd.bsky.social
#Cancer #OncoDaily #Oncology #Medicine #Health
Can mpMRI replace TURBT for faster treatment in MIBC?
A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social
ascopubs.org/doi/10.1200/JC…
A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social
ascopubs.org/doi/10.1200/JC…
January 15, 2025 at 8:25 PM
Can mpMRI replace TURBT for faster treatment in MIBC?
A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social
ascopubs.org/doi/10.1200/JC…
A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social
ascopubs.org/doi/10.1200/JC…
Great working with Patrick Squires and the Merck team on this MIBC RWA #gu25 @ascocancer.bsky.social
February 15, 2025 at 12:35 AM
Great working with Patrick Squires and the Merck team on this MIBC RWA #gu25 @ascocancer.bsky.social
April 4, 2026 at 6:07 AM
Can some MIBC patients safely skip cystectomy?
In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%.
@oncoalert.bsky.social
@oncbrothers.bsky.social
@erplimackmd.bsky.social
doi.org/10.1200/JCO-...
In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%.
@oncoalert.bsky.social
@oncbrothers.bsky.social
@erplimackmd.bsky.social
doi.org/10.1200/JCO-...
December 18, 2024 at 11:58 AM
Can some MIBC patients safely skip cystectomy?
In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%.
@oncoalert.bsky.social
@oncbrothers.bsky.social
@erplimackmd.bsky.social
doi.org/10.1200/JCO-...
In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%.
@oncoalert.bsky.social
@oncbrothers.bsky.social
@erplimackmd.bsky.social
doi.org/10.1200/JCO-...
Tian Zhang is Evaluating Enfortumab Vedotin Plus RT for Cisplatin-Ineligible MIBC - David H Aggen
@davidaggen.bsky.social
@tiansterzhangmd.bsky.social
oncodaily.com/voices/david...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@davidaggen.bsky.social
@tiansterzhangmd.bsky.social
oncodaily.com/voices/david...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
David H Aggen: Tian Zhang is Evaluating Enfortumab Vedotin Plus RT for Cisplatin-Ineligible MIBC - OncoDaily
David H Aggen: Tian Zhang is Evaluating Enfortumab Vedotin Plus RT for Cisplatin-Ineligible MIBC / cancer, David Aggen, David H Aggen, MIBC, OncoDaily,
oncodaily.com
October 25, 2025 at 8:00 PM
Tian Zhang is Evaluating Enfortumab Vedotin Plus RT for Cisplatin-Ineligible MIBC - David H Aggen
@davidaggen.bsky.social
@tiansterzhangmd.bsky.social
oncodaily.com/voices/david...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@davidaggen.bsky.social
@tiansterzhangmd.bsky.social
oncodaily.com/voices/david...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Across the state of Maine, a quiet cultivation of compassionate care has taken root. Thirty residential care agencies owned and operated by immigrants from Africa have united to form Maine Immigrant Business Coalition (MIBC).
5pt thread shares experiences to contrast this admin's fraud accusations.
5pt thread shares experiences to contrast this admin's fraud accusations.
The experiences in this report stand in stark contrast to the fraud accusations facing immigrant care providers in the state, and nationally. We've compiled excerpts from it, and news about it. Take a look.
#Maine #immigrants #refugees #asylumseekers #mainecaregivers
#Maine #immigrants #refugees #asylumseekers #mainecaregivers
July 2, 2026 at 8:36 PM
Across the state of Maine, a quiet cultivation of compassionate care has taken root. Thirty residential care agencies owned and operated by immigrants from Africa have united to form Maine Immigrant Business Coalition (MIBC).
5pt thread shares experiences to contrast this admin's fraud accusations.
5pt thread shares experiences to contrast this admin's fraud accusations.
NURE-Combo trial: Neoadjuvant nivolumab + nab-paclitaxel achieved a 32.3% pathologic CR (ypT0N0) and 70.9% major pathologic response (ypT≤1N0-x) in MIBC. 12-month EFS: 89.8%. Promising results for cisplatin-ineligible patients!
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
December 7, 2024 at 9:12 AM
NURE-Combo trial: Neoadjuvant nivolumab + nab-paclitaxel achieved a 32.3% pathologic CR (ypT0N0) and 70.9% major pathologic response (ypT≤1N0-x) in MIBC. 12-month EFS: 89.8%. Promising results for cisplatin-ineligible patients!
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social
Day One of #BLADDR24
Dr Petros Grivas
Debate: Role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer
Presentation discusses if TOMBOLA is practice changing, and more data is needed
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr Petros Grivas
Debate: Role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer
Presentation discusses if TOMBOLA is practice changing, and more data is needed
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 27, 2024 at 10:09 AM
Day One of #BLADDR24
Dr Petros Grivas
Debate: Role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer
Presentation discusses if TOMBOLA is practice changing, and more data is needed
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr Petros Grivas
Debate: Role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer
Presentation discusses if TOMBOLA is practice changing, and more data is needed
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
The hypoxic ECM and neutrophils in MIBC immunotherapy resistance www.nature.com/articles/s41...
The hypoxic ECM and neutrophils in MIBC immunotherapy resistance - Nature Reviews Urology
In this Review, the authors describe and discuss hypoxia-associated extracellular matrix mechanisms of neutrophil recruitment, polarization and immunosuppression, how these lead to immunotherapy resis...
www.nature.com
October 25, 2025 at 7:23 AM
The hypoxic ECM and neutrophils in MIBC immunotherapy resistance www.nature.com/articles/s41...
Systematic review of radiosensitisation with bladder preserving radiotherapy.
➡️ Use a radiosensitiser wherever possible, doesn't matter which one
➡️ Highest level of evidence for #BCON & #5FUMMC
👏🏽👏🏽👏🏽👇🏽
www.sciencedirect.com/science/arti...
➡️ Use a radiosensitiser wherever possible, doesn't matter which one
➡️ Highest level of evidence for #BCON & #5FUMMC
👏🏽👏🏽👏🏽👇🏽
www.sciencedirect.com/science/arti...
Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials
For selected patients with muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT) incorporating transurethral resection of the tumor and chemor…
www.sciencedirect.com
November 24, 2024 at 9:15 AM
Systematic review of radiosensitisation with bladder preserving radiotherapy.
➡️ Use a radiosensitiser wherever possible, doesn't matter which one
➡️ Highest level of evidence for #BCON & #5FUMMC
👏🏽👏🏽👏🏽👇🏽
www.sciencedirect.com/science/arti...
➡️ Use a radiosensitiser wherever possible, doesn't matter which one
➡️ Highest level of evidence for #BCON & #5FUMMC
👏🏽👏🏽👏🏽👇🏽
www.sciencedirect.com/science/arti...
Day One of #BLADDR24
Dr Maria De Santis
MIBC ESMO congress highlights #BladderCancer
Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr Maria De Santis
MIBC ESMO congress highlights #BladderCancer
Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 27, 2024 at 9:37 AM
Day One of #BLADDR24
Dr Maria De Santis
MIBC ESMO congress highlights #BladderCancer
Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr Maria De Santis
MIBC ESMO congress highlights #BladderCancer
Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC #FDA #oncology #MIBC
www.onclive.com/view/fda-gra...
www.onclive.com/view/fda-gra...
FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC | OncLive
The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.
www.onclive.com
October 22, 2025 at 2:46 PM
FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC #FDA #oncology #MIBC
www.onclive.com/view/fda-gra...
www.onclive.com/view/fda-gra...
Trimodal therapy (TURBT + radiation + chemo) for muscle-invasive bladder cancer offers a great bladder-sparing alternative to surgery, improving survival and local control. #BladderCancer www.sciencedirect.com/science/arti...
Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials
For selected patients with muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT) incorporating transurethral resection of the tumor and chemor…
www.sciencedirect.com
November 24, 2024 at 7:34 AM
Trimodal therapy (TURBT + radiation + chemo) for muscle-invasive bladder cancer offers a great bladder-sparing alternative to surgery, improving survival and local control. #BladderCancer www.sciencedirect.com/science/arti...
Hinley et al.: Connexin 32 sustains urothelial quiescence and limits TGFβ-driven remodelling, revealing a luminal MIBC split.
@biologyatyork.bsky.social @ybri-uoy.bsky.social @jennybaker.bsky.social @drsimonbaker.bsky.social @asmasonomics.bsky.social
www.life-science-alliance.org/content/9/5/...
@biologyatyork.bsky.social @ybri-uoy.bsky.social @jennybaker.bsky.social @drsimonbaker.bsky.social @asmasonomics.bsky.social
www.life-science-alliance.org/content/9/5/...
February 20, 2026 at 4:05 PM
Hinley et al.: Connexin 32 sustains urothelial quiescence and limits TGFβ-driven remodelling, revealing a luminal MIBC split.
@biologyatyork.bsky.social @ybri-uoy.bsky.social @jennybaker.bsky.social @drsimonbaker.bsky.social @asmasonomics.bsky.social
www.life-science-alliance.org/content/9/5/...
@biologyatyork.bsky.social @ybri-uoy.bsky.social @jennybaker.bsky.social @drsimonbaker.bsky.social @asmasonomics.bsky.social
www.life-science-alliance.org/content/9/5/...
Out today: Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive #BladderCancer, a #ResearchWatch summary of recent clinical findings by Roger Li, James J. Mulé, Jose R. Conejo-Garcia, and colleagues.
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive Bladder Cancer
Major Finding: A phase 1b trial demonstrated the safety of cretostimogene grenadenorepvec plus nivolumab in muscle-invasive bladder cancer (MIBC).Concept: Boosting immune checkpoint inhibition with on...
aacrjournals.org
December 4, 2024 at 4:00 PM
Out today: Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive #BladderCancer, a #ResearchWatch summary of recent clinical findings by Roger Li, James J. Mulé, Jose R. Conejo-Garcia, and colleagues.
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Merck $MRK: periop MIBC EFS via KEYTRUDA+Padcev shfits HTA; buy now.
September 20, 2026 at 8:01 PM
Merck $MRK: periop MIBC EFS via KEYTRUDA+Padcev shfits HTA; buy now.
Dr. Daniel Petrylak talks with @medscape.com about the increasing opportunities for bladder preservation with muscle-invasive #bladdercancer. #MIBC
medscape.com/viewarticle/...
@oncoalert.bsky.social
medscape.com/viewarticle/...
@oncoalert.bsky.social
Q&A: Can More Patients With MIBC Keep Their Bladder?
Rapid developments in muscle-invasive bladder cancer treatment are leading to new approaches to bladder preservation.
medscape.com
July 3, 2026 at 1:18 PM
Dr. Daniel Petrylak talks with @medscape.com about the increasing opportunities for bladder preservation with muscle-invasive #bladdercancer. #MIBC
medscape.com/viewarticle/...
@oncoalert.bsky.social
medscape.com/viewarticle/...
@oncoalert.bsky.social
News From Industry
Source: AstraZeneca
The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial.
buff.ly/iAklr92
Source: AstraZeneca
The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial.
buff.ly/iAklr92
July 4, 2025 at 9:04 AM
News From Industry
Source: AstraZeneca
The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial.
buff.ly/iAklr92
Source: AstraZeneca
The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial.
buff.ly/iAklr92
Great idea to look for most important recent #BladderCancer papers. There is a lot going in both the advanced and also in the localized disease setting right now #NMIBC #MIBC indicating a potential also for bladder-sparing approaches
To echo @dr-coops.bsky.social i thought we could thread some of the most interesting #BladderCancer papers over the last few months ... that might have missed discussion @alisonbirtle.bsky.social @bladdercancer.bsky.social .....
November 19, 2024 at 10:26 AM
Great idea to look for most important recent #BladderCancer papers. There is a lot going in both the advanced and also in the localized disease setting right now #NMIBC #MIBC indicating a potential also for bladder-sparing approaches
So happy for you! As a survivor of stage 4 MIBC, I’m sure you are feeling relieved! 🙏🏻 we couldn’t do without you!
August 29, 2026 at 2:07 AM
So happy for you! As a survivor of stage 4 MIBC, I’m sure you are feeling relieved! 🙏🏻 we couldn’t do without you!
Phase 2 trial results suggest the antibody-drug conjugate SHR-A2102 combined with adebrelimab yields a favorable pathologic complete response in MIBC.
https://www.renalandurologynews.com/reports/bladder-cancer-mibc-perioperative-shr-a2102-adebrelimab-treatment/ #ASCO26
https://www.renalandurologynews.com/reports/bladder-cancer-mibc-perioperative-shr-a2102-adebrelimab-treatment/ #ASCO26
Perioperative SHR-A2102 Plus Adebrelimab Shows Promise for MIBC - Renal and Urology News
SHR-A2102 is a novel antibody-drug conjugate targeting nectin-4 with a topoisomerase 1 inhibitor payload. A phase 2/3 study tested SHR-A2102 combined with adebrelimab as perioperative therapy for musc...
www.renalandurologynews.com
June 16, 2026 at 2:51 PM
Phase 2 trial results suggest the antibody-drug conjugate SHR-A2102 combined with adebrelimab yields a favorable pathologic complete response in MIBC.
https://www.renalandurologynews.com/reports/bladder-cancer-mibc-perioperative-shr-a2102-adebrelimab-treatment/ #ASCO26
https://www.renalandurologynews.com/reports/bladder-cancer-mibc-perioperative-shr-a2102-adebrelimab-treatment/ #ASCO26